

Mylan Inc.
1000 Mylan Boulevard
Canonsburg, PA 15317, United States

Date: January 5, 2026

BSE Limited

Phiroze Jeejeebhoy Towers
Dalal Street, Fort
Mumbai 400 001

E-mail: corp.relations@bseindia.com

National Stock Exchange of India Limited

Exchange Plaza,
Bandra-Kurla-Complex, Bandra (East)
Mumbai – 400 051

Email: takeover@nse.co.in

Company Secretary

Biocon Limited

20th KM, Hosur Road
Electronic City, Bangalore 560 100, India

E-mail: co.secretary@biocon.com

Dear Sir/ Madam,

Subject: Disclosure under Regulation 29(1) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations 2011 (“SEBI (SAST) Regulations”).

This is to inform you that we, Mylan Inc., have been allotted 9,19,67,019 equity shares, of Biocon Limited, by way of a preferential issue on a private placement basis, on January 5, 2026.

In view of the above, please find attached the disclosure under Regulation 29(1) of the SEBI (SAST) Regulations.

[signature page to follow]

Thanking you,

Yours faithfully,
For **Mylan Inc.**

Signed by:


4986D9D7DA95460...

Name: John Miraglia
Designation: President

Disclosures under Regulation 29(1) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 ("SEBI (SAST) Regulations")

Part-A- Details of the Acquisition

Name of the Target Company (TC)	Biocon Limited		
Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer	Mylan Inc.		
Whether the acquirer belongs to Promoter/Promoter group	No		
Name(s) of the Stock Exchange(s) where the shares of TC are Listed	BSE Limited National Stock Exchange of India Limited		
Details of the acquisition as follows	Number	% w.r.t. total share/voting capital wherever applicable (*)	% w.r.t. total diluted share/voting capital of the TC (**)
Before the acquisition under consideration, holding of acquirer along with PACs of:			
a) Shares carrying voting rights	Nil	Nil	Nil
b) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ other)	Nil	Nil	Nil
c) Voting rights (VR) otherwise than by equity shares	Nil	Nil	Nil
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category)	Nil	Nil	Nil
e) Total (a+b+c+d)	Nil	Nil	Nil
Details of acquisition:			
a) Shares carrying voting rights acquired	9,19,67,019	6.88	6.10
b) VRs acquired otherwise than by equity shares	Nil	Nil	Nil
c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the	Nil	Nil	Nil

TC (specify holding in each category) acquired			
d) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)	Nil	Nil	Nil
e) Total (a+b+c+/-d)	9,19,67,019	6.88	6.10
After the acquisition, holding of acquirer along with PACs of:			
a) Shares carrying voting rights	9,19,67,019	6.88	6.10
b) VRs otherwise than by equity shares	Nil	Nil	Nil
c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition	Nil	Nil	Nil
d) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ other)	Nil	Nil	Nil
e) Total (a+b+c+d)	9,19,67,019	6.88	6.10
Mode of acquisition (e.g. open market/ public issue/ rights issue/ preferential allotment/ inter-se transfer/encumbrance, etc.)	Acquisition of 9,19,67,019 equity shares by way of preferential allotment		
Salient features of the securities acquired including time till redemption, ratio at which it can be converted into equity shares, etc	Not Applicable.		
Date of acquisition of/ date of receipt of intimation of allotment of shares/ VR/ warrants/ convertible securities/ any other instrument that entitles the acquirer to receive shares in the TC	January 5, 2026		
Equity share capital / total voting capital of the TC before the said acquisition	INR 6,68,48,18,175/- divided into 1,33,69,63,635 equity shares having face value of INR 5/- each		
Equity share capital/ total voting capital of the TC after the said acquisition	INR 7,54,12,15,940 divided into 1,50,82,43,188 equity shares having face value of INR 5/- each		
Total diluted share/voting capital of the TC after the said acquisition	INR 7,54,12,15,940 divided into 1,50,82,43,188 equity shares having face value of INR 5/- each		

Notes:

(*) Total share capital/ voting capital to be taken as per the latest filing done by the company to the Stock Exchange under Clause 35 of the Listing Agreement.

(**) Diluted share/voting capital means the total number of shares in the Target Company assuming full conversion of the outstanding convertible securities/warrants into equity shares of the Target Company.

[signature page to follow]

For and on behalf of **Mylan Inc.**

Signed by:


4986D9D7DA95460...

Name: John Miraglia

Designation: President

Place: 1000 Mylan Boulevard

Canonsburg, PA 15317, United States

Date: January 5, 2026

Part-B***

Name of the Target Company: Biocon Limited

Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer	Whether the acquirer belongs to Promoter/ Promoter group	PAN of the acquirer and/ or PACs
Mylan Inc.	No	AAQCM0517P

Note:

(***) Part-B shall be disclosed to the Stock Exchanges but shall not be disseminated.

[signature page to follow]

For and on behalf of **Mylan Inc.**

Signed by:


4986D9D7DA95460...

Name: John Miraglia
Designation: President

Place: 1000 Mylan Boulevard
Canonsburg, PA 15317, United States
Date: January 5, 2026